Search research articles
Contact Us
Filters
Showing results (151-160 of 171) with videos related to
Page
of 18
Sort By:
The Oncologist
|
August 29, 2022
Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on Race
Raquel Zimmerman, Mehmet A Bilen, Elisabeth I Heath, et al.
Current Oncology (Toronto, Ont.)
|
March 26, 2025
Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma
Julie Williamson, Muhammad Zaki Hidayatullah Fadlullah, Magdalena Kovacsovics-Bankowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 17, 2024
Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline
Nadine Tung, Charité Ricker, Hans Messersmith, et al.
JAMA Network Open
|
August 20, 2025
Statin Use in Patients With Advanced Prostate Cancer in the TITAN and SPARTAN Trials
Soumyajit Roy, Zeynep Irem Ozay, Avirup Guha, et al.
Frontiers in Oncology
|
October 3, 2022
Genomic landscape of advanced prostate cancer patients with <i>BRCA1</i> versus <i>BRCA2</i> mutations as detected by comprehensive genomic profiling of cell-free DNA
Umang Swami, Raquel Mae Zimmerman, Roberto H Nussenzveig, et al.
Journal for Immunotherapy of Cancer
|
January 17, 2024
Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4<sup>+</sup> naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma
Magdalena Kovacsovics-Bankowski, Johanna M Sweere, Connor P Healy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 1, 2024
Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer
Yohann Loriot, Arjun V Balar, Daniel P Petrylak, et al.
Future Oncology (London, England)
|
April 2, 2026
How enfortumab vedotin plus pembrolizumab affects the quality of life of people with advanced urothelial cancer compared with platinum-based chemotherapy: a plain language summary of patient-reported outcomes from the EV-302 study
Shilpa Gupta, Yohann Loriot, Michiel S Van der Heijden, et al.
Cancer
|
December 20, 2025
Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials
Georges Gebrael, Neeraj Agarwal, Alicia K Morgans, et al.
The Lancet. Oncology
|
May 31, 2025
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study
Shilpa Gupta, Yohann Loriot, Michiel S Van der Heijden, et al.
Page
of 18
Search research articles
Search
Showing results (151-160 of 171) with videos related to
Sort By:
Page
of 18
The Oncologist
|
August 29, 2022
Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on Race
Raquel Zimmerman, Mehmet A Bilen, Elisabeth I Heath, et al.
Current Oncology (Toronto, Ont.)
|
March 26, 2025
Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma
Julie Williamson, Muhammad Zaki Hidayatullah Fadlullah, Magdalena Kovacsovics-Bankowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 17, 2024
Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline
Nadine Tung, Charité Ricker, Hans Messersmith, et al.
JAMA Network Open
|
August 20, 2025
Statin Use in Patients With Advanced Prostate Cancer in the TITAN and SPARTAN Trials
Soumyajit Roy, Zeynep Irem Ozay, Avirup Guha, et al.
Frontiers in Oncology
|
October 3, 2022
Genomic landscape of advanced prostate cancer patients with <i>BRCA1</i> versus <i>BRCA2</i> mutations as detected by comprehensive genomic profiling of cell-free DNA
Umang Swami, Raquel Mae Zimmerman, Roberto H Nussenzveig, et al.
Journal for Immunotherapy of Cancer
|
January 17, 2024
Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4<sup>+</sup> naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma
Magdalena Kovacsovics-Bankowski, Johanna M Sweere, Connor P Healy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 1, 2024
Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer
Yohann Loriot, Arjun V Balar, Daniel P Petrylak, et al.
Future Oncology (London, England)
|
April 2, 2026
How enfortumab vedotin plus pembrolizumab affects the quality of life of people with advanced urothelial cancer compared with platinum-based chemotherapy: a plain language summary of patient-reported outcomes from the EV-302 study
Shilpa Gupta, Yohann Loriot, Michiel S Van der Heijden, et al.
Cancer
|
December 20, 2025
Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials
Georges Gebrael, Neeraj Agarwal, Alicia K Morgans, et al.
The Lancet. Oncology
|
May 31, 2025
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study
Shilpa Gupta, Yohann Loriot, Michiel S Van der Heijden, et al.
Page
of 18